Natural Vitamin E
D’Alpha Tocopheryl Acetate Softgel Capsules
400 iu Softgel Capsules Contain 1332% USDA of Natural Vitamin E
| $9.99 | 100 Count Bottle VP504R | Retails for $11.90 | |
| $99.99 | 12 bottles 100 Count each | Retail Value $142.80 | |
| $22.99 | 250 Count Bottle VP504U | Retails for $27.90 | |
|
Display An Attractive 12 Bottle Case On Your Counter for Patient/Client Convenience. Additional Wholesale Discounts Available |
|||
Tweet
Pure Natural Vitamin E D’Alpha Tocopheryl made from premium quality soy sources.
No caffeine, corn, gluten, dairy, egg, sodium, starch, sugar, wheat, yeast, artificial colorings, flavorings or preservatives. added.
Because Vitamin E helps maintain red blood cell health, it is helpful in supplying oxygen to muscles including your heart muscle. Vitamin E protects cells from free radical damage.
Find Natural Vitamin E D’Alpha Tocopheryl Supplements at a Featured Merchant (below)
Vitamin E is essential to human nutrition because it supplies oxygen to the heart and the other muscles in the body.
- It prevents unstable molecules known as free radicals from damaging cells and tissue
- Accelerates wound healing
- Protects lung tissue from inhaled pollutants
- Aids in functioning of the immune system, endocrine system and sex glands
- Improves circulation
- And promotes normal blood clotting
Vitamin E is a fat-soluble vitamin. There are eight different forms and each form has its own biological activity. Alpha-tocopherol is the most active form of vitamin E and is a powerful biological antioxidant. Antioxidants such as vitamin E act to protect your cells against the effects of free radicals, which are by-products of the body’s metabolism.
Vitamin E Valuable To Battle Prostate Cancer
Survival rates of men with prostate cancer might soon be increased with a new vitamin E treatment which could significantly reduce tumor regrowth.
Queensland University of Technology (QUT) Australia prostate cancer researchers are leading the fight against the disease. A team of research scientists have identified a particular constituent of vitamin E, known as tocotrienol (T3), which can inhibit the growth of prostate tumors.
This research has been funded by Davos Life Science in Singapore to undertake a one-year study of the long-term effectiveness of T3 to prevent the recurrence of treated prostate cancer tumors.
"Prostate cancer is the most common type of cancer in developed countries," the researchers said. "It is responsible for more male deaths than any other cancer, except lung cancer."
They said existing chemotherapy and hormonal therapy treatment of prostate cancer was insufficient because it failed to kill off the prostate cancer stem cells (CSCs) which were believed to be responsible for the regrowth of tumors.
However, the research team have discovered a particular form of T3, called gamma-tocotrienol (γ-T3), can successfully kill off the prostate cancer CSCs.
"Currently there is no effective treatment for metastatic prostate cancer, because it grows back after conventional therapies in more than 70 per cent of cases," they said.
"But with γ-T3, QUT researchers have found a better way to treat prostate cancer, which has the potential to inhibit recurrence of the disease."
In laboratory trials, γ-T3 completely inhibited tumor formation in more than 70 per cent of the subjects implanted with prostate cancer cells and fed the vitamin E constituent in water. In the remaining cases, tumor regrowth was considerably reduced, while tumours reformed in 100 per cent of the control group. The findings were published recently in the International Journal of Cancer.
The next stage of this study has begun and will determine the long-term effectiveness of the γ-T3 treatment, with plans to progress to clinical trials in the future.
"Previous clinical trials using another vitamin E constituent to inhibit prostate cancer development were unsuccessful, but these trials did not use the vitamin E constituent γ-T3," they said.
"Other research has found γ-T3 is also effective in suppressing other types of cancer, including breast, colon, liver and gastric."
"Collaboration, which combines the expertise of researchers from different disciplines and institutions to achieve common goals, will lead to better solutions," the researchers said.
TRI is a collaboration of QUT, the University of Queensland, Princess Alexandra Hospital and the Mater Medical Research Institute, with funding from the Australian Government, Queensland Government, The Atlantic Philanthropies, QUT and UQ.
The research team is based at IHBI and the Australian Prostate Cancer Research Centre -- Queensland, a comprehensive research centre to investigate new ways to treat prostate cancer established by QUT and the Princess Alexandra Hospital with funding from the federal government.
This research is funded by world-leading tocotrienol manufacturer Davos Life Science. The Singapore-based company produces γ-T3 from sustainable palm plantations.
Story Source: Queensland University of Technology.
This article is not intended to provide medical advice, diagnosis or treatment.
